News Image

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Provided By GlobeNewswire

Last update: Sep 23, 2024

Châtillon, France, September 23, 2024

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that patient screening is complete for the Phase 3 trial, VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy), using the modified Viaskin Peanut Patch in children ages 4 – 7 years old with peanut allergy.

Read more at globenewswire.com

DBV TECHNOLOGIES SA-SPON ADR

NASDAQ:DBVT (2/21/2025, 8:12:30 PM)

After market: 4.4 +0.01 (+0.11%)

4.395

+0.13 (+3.17%)



Find more stocks in the Stock Screener

Follow ChartMill for more